| Identification | Back Directory | [Name]
H 835 | [CAS]
8004-31-7 | [Synonyms]
H 835 Acrinor Decrinor 3,7-Dihydro-7-(2-(((1S,2R)-2-hydroxy-1-methyl-2-phenylethyl)amino)ethyl)-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride, mixt. with 7-(2-((2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)amino)ethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride 1H-Purine-2,6-dione, 3,7-dihydro-7-(2-(((1S,2R)-2-hydroxy-1-methyl-2-phenylethyl)amino)ethyl)-1,3-dimethyl-, monohydrochloride, mixt. with 7-(2-((2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)amino)ethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride | [Molecular Formula]
C35H46Cl2N10O8 | [MOL File]
8004-31-7.mol | [Molecular Weight]
805.72 |
| Hazard Information | Back Directory | [Description]
Acrinor is a adrenergic beta receptor agonist. | [Uses]
Cafedrine-theodrenaline can stimulate the cardiovascular system through β-adrenergic receptor mediation, increasing arterial pressure, stroke volume, and cardiac output, while reducing peripheral vascular resistance, thereby supporting overall cardiac function. Cafedrine-theodrenaline helps maintain blood pressure during hypotensive episodes without causing significant tachycardia[1]. | [IC 50]
β-adrenoceptor | [References]
[1] Sternitzke N, et al. Effect of Akrinor on cardiovascular-dynamics before and after blockade of adrenergic beta-receptors by propranolol[J]. Zeitschrift fur Kardiologie, 1975, 64(5): 419-430. PMID:1189536 |
|
|